MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company Book Value 2011-2026 | LLY
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112 B | 78.7 B | 64 B | 49.5 B | 48.8 B | 46.6 B | 2.7 B | 10.9 B | 11.7 B | 14.1 B | 14.6 B | 15.4 B | 17.6 B | 14.8 B | 13.5 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 112 B | 2.7 B | 34.4 B |
Quarterly Book Value Eli Lilly and Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101 B | 89.4 B | 75.6 B | 71.9 B | 63.9 B | 57.9 B | 54.8 B | 53.2 B | 49.5 B | 47.5 B | - | 46.9 B | 48.8 B | 48.2 B | 47.8 B | 46.8 B | 46.6 B | 46.6 B | 46.6 B | 46.6 B | 39.3 B | 39.3 B | 39.3 B | 39.3 B | 43.9 B | 43.9 B | 43.9 B | 43.9 B | 45 B | 45 B | 45 B | 45 B | 38.8 B | 38.8 B | 38.8 B | 38.8 B | 35.6 B | 35.6 B | 35.6 B | 35.6 B | 36.3 B | 37.1 B | 37.1 B | 37.2 B | 35.2 B | 35.2 B | 35.2 B | 35.2 B | 34.4 B | 34.4 B | 34.4 B | 34.4 B | 33.7 B | 33.7 B | 33.7 B | 33.7 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 101 B | 33.7 B | 44.7 B |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
29 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.7 | 3.35 % | $ 199 M | USA |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M | China |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 31.61 | 2.46 % | $ 2.1 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B | France |
 |
BioNTech SE
BNTX
|
19.2 B | $ 93.75 | 1.62 % | $ 22.7 B | Germany |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B |  Britain |
 |
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 53.6 | 3.9 % | $ 4.82 B |  Schweiz |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M |  Israel |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.68 | 0.94 % | $ 250 M | Israel |
 |
Abcam plc
ABCM
|
727 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
6.55 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M | Britain |
|
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.81 | 18.2 % | $ 37 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
26.2 M | $ 31.59 | 0.94 % | $ 850 M | USA |
 |
Affimed N.V.
AFMD
|
97.2 M | - | -34.95 % | $ 21.5 M | Germany |
|
Forte Biosciences
FBRX
|
61 M | $ 21.99 | 0.23 % | $ 285 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Celyad Oncology SA
CYAD
|
19.7 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
142 M | - | -7.31 % | $ 87 M | USA |
 |
Galectin Therapeutics
GALT
|
-126 M | $ 2.69 | -3.71 % | $ 172 M | USA |
 |
Generation Bio Co.
GBIO
|
86.2 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
-6.6 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | Israel |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 8.02 | 0.06 % | $ 5.45 B |  Spain |
 |
Hutchison China MediTech Limited
HCM
|
1.25 B | $ 11.78 | 0.26 % | $ 10.1 B | China |
 |
Cyclacel Pharmaceuticals
CYCCP
|
6.84 M | - | -4.36 % | $ 27 M | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
52.4 M | - | - | $ 384 M | Britain |
 |
Heron Therapeutics
HRTX
|
14.3 M | $ 0.9 | 1.4 % | $ 150 M | USA |
 |
Gracell Biotechnologies
GRCL
|
1.38 B | - | - | $ 3.37 B | China |
 |
Anika Therapeutics
ANIK
|
190 M | $ 14.75 | -0.97 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
3.84 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.31 | -3.88 % | $ 5.45 M | Israel |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |